Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER vs BIAXIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
Acute bacterial exacerbation of chronic bronchitis,Acute maxillary sinusitis,Community-acquired pneumonia,Pharyngitis/tonsillitis,Uncomplicated skin and skin structure infections,Helicobacter pylori eradication (as part of triple or dual therapy),Mycobacterium avium complex prophylaxis and treatment (off-label for some indications)
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Terminal elimination half-life: 3-7 hours (single dose, 250-500 mg); with multiple dosing, half-life may extend to 7-10 hours due to saturable metabolism. Clinical context: Shorter half-life requires twice-daily dosing; extended half-life (via 14-hydroxy metabolite, t1/2 ~11 h) contributes to antibacterial activity.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Primarily metabolized by CYP3A4 isoenzyme; clarithromycin undergoes first-pass metabolism to form 14-hydroxyclarithromycin (active metabolite).
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Approximately 20-30% of administered dose is excreted unchanged in urine; remainder is hepatically metabolized and excreted in bile and feces (~50% fecal elimination).
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
65-75% bound, primarily to albumin and alpha-1-acid glycoprotein.
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Vd: 2.6-3.5 L/kg. Clinical meaning: Large Vd indicates extensive tissue penetration, including lungs, tonsils, and sinuses, exceeding serum concentrations.
Intravenous: 100%.
Oral bioavailability: 50-55% (250 mg tablet); may be increased to 60-70% when administered with food. Intravenous: 100%.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
Cr Cl <30 m L/min: reduce dose by 50%; Cr Cl <10 m L/min: not recommended; no adjustment for Cr Cl >30 m L/min
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Child-Pugh Class C: reduce dose by 50% or consider alternative; mild to moderate hepatic impairment: no adjustment
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
15 mg/kg/day orally divided every 12 hours; maximum 500 mg/day for 10 days; for extended-release, not recommended for children <12 years
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
No specific dose adjustment; monitor renal function and adjust per renal guidelines; increased risk of QT prolongation
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
None
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Increased risk of cardiac arrhythmias, including QT prolongation and torsades de pointes; avoid in patients with known QT prolongation or concurrent use with QT-prolonging drugs.,Potential for hepatotoxicity (elevated liver enzymes, hepatitis); monitor liver function.,Exacerbation of myasthenia gravis symptoms.,Clostridioides difficile-associated diarrhea (CDAD).,Drug interactions via CYP3A4 inhibition (e.g., statins, warfarin, colchicine, and other macrolides).,Pregnancy Category C; avoid use unless no alternative (clarithromycin associated with increased risk of miscarriage and fetal abnormalities in animal studies).
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
Hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic.,Concurrent use with pimozide, ergotamine, dihydroergotamine, lovastatin, simvastatin, or colchicine in renal/hepatic impairment.,History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.,QT prolongation or history of ventricular arrhythmias (including torsades de pointes).,Concurrent use with antiarrhythmics (e.g., quinidine, procainamide, amiodarone) or other QT-prolonging drugs.,Severe hepatic failure or acute porphyria.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
Grapefruit and grapefruit juice should be avoided as they inhibit CYP3A4 and may increase clarithromycin levels, raising risk of QT prolongation. High-fat meals may delay absorption but do not significantly alter total exposure. Alcohol is not specifically contraindicated but may increase gastrointestinal irritation; avoid concurrent use of statins (especially simvastatin, lovastatin) due to increased myopathy risk.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
FDA Pregnancy Category C. Animal studies have shown fetal harm (cleft palate, skeletal abnormalities) at doses 2-5 times the human clinical dose. No adequate human studies. First trimester: Avoid unless benefit justifies risk. Second and third trimesters: Limited data; use only if clearly needed. Monitor for potential maternal hepatotoxicity.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
Clarithromycin is excreted into human breast milk; the milk-to-plasma ratio is approximately 0.25-0.5. Infants exposed via breast milk may experience gastrointestinal disturbances or altered gut flora. Use with caution, especially in infants younger than 6 weeks of age due to risk of hypertrophic pyloric stenosis. Consider temporary discontinuation during therapy if high doses are used.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
No specific pharmacokinetic studies have demonstrated a need for dose adjustment during pregnancy. However, pregnancy can increase volume of distribution and renal clearance; empirical dose monitoring is not required. Standard dosing regimens are applied unless hepatic or renal impairment is present.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
Biaxin (clarithromycin) is a macrolide antibiotic with activity against atypical pathogens (e.g., Legionella, Mycoplasma, Chlamydia). It is a potent CYP3A4 inhibitor, increasing levels of statins, warfarin, and colchicine. Use caution in myasthenia gravis; may exacerbate weakness. QT prolongation risk: avoid use with other QT-prolonging drugs, correct electrolyte abnormalities. For H. pylori eradication, combine with amoxicillin and a PPI as first-line. Renal dose adjustment required for Cr Cl <30 m L/min.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
Take with or without food, but taking with food may reduce stomach upset.,Complete the full course even if you feel better to prevent resistance.,Avoid grapefruit or grapefruit juice while on this medication.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea/vomiting.,May cause metallic or bitter taste in the mouth; this is usually temporary.,Tell your doctor if you have myasthenia gravis, as clarithromycin can worsen symptoms.,Avoid driving or operating heavy machinery if you experience dizziness or vision changes.,Use effective contraception if applicable; clarithromycin may reduce oral contraceptive efficacy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER vs BIAXIN, answered by our medical review team.
ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. BIAXIN is a Macrolide Antibiotic that works by Binds to the 50S ribosomal subunit, inhibiting bacterial protein synthesis by blocking peptide chain elongation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER and BIAXIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. The standard adult dose of BIAXIN is: 250-500 mg orally every 12 hours for 7-14 days; extended-release: 1000 mg orally every 24 hours for 7-14 days. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER and BIAXIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. BIAXIN is classified as Category C. FDA Pregnancy Category C. Animal studies have shown fetal harm (cleft palate, skeletal abnormalities) at doses 2-5 times the human clinical dose. No adequate human studies. First t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.